<h2 data-section-id="znhwv6" data-start="0" data-end="12"><strong>Interstitial Lung Disease Market</strong></h2>
<p data-start="13" data-end="606">The Interstitial Lung Disease (ILD) market is witnessing notable growth across the 7MM, driven by rising disease prevalence, improved diagnostic technologies, and expanding therapeutic innovation. In 2025, the ILD market size reached nearly USD 6 billion, with the United States accounting for approximately 83% of the total market share. The market is projected to grow at a CAGR of 8.7% during 2026-2036. Current therapies, including <span class="whitespace-normal">OFEV</span> and <span class="whitespace-normal">ACTEMRA</span>, primarily slow fibrosis progression rather than reverse disease pathology.</p>
<ul data-start="608" data-end="857">
<li data-section-id="6hzset" data-start="608" data-end="675">Rising awareness and earlier diagnosis support market expansion</li>
<li data-section-id="1ym0hfv" data-start="676" data-end="735">High unmet need for disease-modifying therapies remains</li>
<li data-section-id="1j347l4" data-start="736" data-end="799">JASCAYD is expected to generate the highest revenue by 2036</li>
<li data-section-id="v5erp5" data-start="800" data-end="857">Increasing competition may intensify pricing pressure</li>
</ul>
<h2 data-section-id="1uvesjx" data-start="859" data-end="877"><strong>Interstitial Lung Disease Epidemiology</strong></h2>
<p data-start="878" data-end="1541">Interstitial Lung Disease represents a heterogeneous group of chronic pulmonary disorders characterized by inflammation and fibrosis of lung tissue. In 2025, the total diagnosed prevalent ILD cases across the 7MM were estimated at nearly 1.3 million. The United States alone reported around 420K treated cases. Epidemiological trends indicate a slightly higher disease burden among females compared to males in the US population. Sarcoidosis emerged as the most prevalent ILD subtype across EU4 and the UK. Increasing utilization of imaging techniques, pulmonary function tests, and multidisciplinary diagnosis is improving identification rates of ILD globally.</p>
<ul data-start="1543" data-end="1758">
<li data-section-id="1swg7pj" data-start="1543" data-end="1596">Diagnosed prevalent cases in the 7MM: 1.3 million</li>
<li data-section-id="12ns6p2" data-start="1597" data-end="1634">Treated ILD cases in the US: 420K</li>
<li data-section-id="1qypj71" data-start="1635" data-end="1666">Female cases in the US: 56%</li>
<li data-section-id="8da765" data-start="1667" data-end="1696">Male cases in the US: 44%</li>
<li data-section-id="7vpo0d" data-start="1697" data-end="1758">Sarcoidosis was the leading ILD subtype in EU4 and the UK</li>
</ul>
<h2 data-section-id="10hi5us" data-start="1760" data-end="1774"><strong>Interstitial Lung Disease Pipeline</strong></h2>
<p data-start="1775" data-end="2393">The <a href="https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight"><strong>ILD pipeline</strong></a> is expanding rapidly with the development of antifibrotic, <a href="https://www.delveinsight.com/report-store/immunomodulators-market"><strong>immunomodulatory</strong></a>, and inhaled prostacyclin-based therapies aimed at improving efficacy and tolerability. Several investigational drugs are focusing on localized pulmonary delivery to minimize systemic toxicity and improve long-term adherence. Companies are actively exploring therapies targeting inflammatory and fibrotic pathways associated with disease progression. Emerging therapies are expected to address major unmet needs such as limited disease modification, poor tolerability, and lack of biomarker-driven treatment stratification.</p>
<h3 data-start="2395" data-end="2415"><strong data-start="2395" data-end="2413">Emerging Drugs</strong></h3>
<ul data-start="2416" data-end="2653">
<li data-section-id="1glafog" data-start="2416" data-end="2510"><a href="https://www.delveinsight.com/report-store/benlysta-belimumab-drug-insight-market-forecast"><strong><span class="whitespace-normal">Belimumab</span></strong></a> - developed by <span class="whitespace-normal">GSK</span></li>
<li data-section-id="kxkqwo" data-start="2511" data-end="2570">Treprostinil palmitil inhalation powder (TPIP) - Insmed</li>
<li data-section-id="l9t0xz" data-start="2571" data-end="2621">Seralutinib - Gossamer Bio/Chiesi Farmaceutici</li>
<li data-section-id="x210r1" data-start="2622" data-end="2653"><a href="https://www.delveinsight.com/report-store/l606-emerging-drug-insight-and-market-forecast"><strong>L606</strong></a> - Liquidia Corporation</li>
</ul>
<p data-start="2655" data-end="2741" data-is-last-node="" data-is-only-node="">Novel inhaled therapies are anticipated to reshape the future ILD treatment landscape.</p>

Interstitial Lung Disease Market

Interstitial Lung Disease Market Infographic

Interstitial Lung Disease Market Thumbnail

Interstitial Lung Disease Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape